Pulmonary Tuberculosis and
            <i>Mycobacterium Tuberculosis:</i>
            Modern Molecular Epidemiology and Perspectives

Godreuil, Sylvain; Tazi, Loubna; Bañuls, Anne‐Laure

doi:10.1002/9780470114209.ch1

Cited by 17 publications

(22 citation statements)

References 194 publications

(256 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The solids were collected to leave 4 (4.11 g, 95%) as light yellow crystals: mp 87.5−88°C (lit. 28 80°C); R f = 0.26 (hexanes/ ethyl acetate, 5:1); 1 H NMR (CDCl 3 3-(Benzyloxy)-2-nitrophenol (5). A solution of dibenzyl ether 4 (3.0 g, 8.95 mmol) in dichloromethane (80 mL) at −78°C was treated dropwise with boron trichloride (13 mL, 1 M in heptane) during which the color changed to dark purple.…”

Section: ■ Experimental Sectionmentioning

confidence: 99%

Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases

Gill

Kirchhoff

et al. 2012

J. Med. Chem.

View full text Add to dashboard Cite

By utilization of three-dimensional structure information of rifamycins bound to RNA polymerase (RNAP) and the human pregnane X receptor (hPXR), representative examples (2b-d) of a novel subclass of benzoxazinorifamycins have been synthesized. Relative to rifalazil (2a), these analogues generally display superior affinity toward wild-type and Rif-resistant mutants of the Mycobacterium tuberculosis RNAP but lowered antitubercular activity in cell culture under both aerobic and anaerobic conditions. Lowered affinity toward hPXR for some of the analogues is also observed, suggesting a potential for reduced Cyp450 induction activity. Mouse and human microsomal studies of analogue 2b show it to have excellent metabolic stability. Mouse pharmacokinetics in plasma and lung show accumulation of 2b but with a half-life suggesting nonoptimal pharmacokinetics. These studies demonstrate proof of principle for this subclass of rifamycins and support further expansion of structure-activity relationships (SARs) toward uncovering analogues with development potential.

show abstract

Section: ■ Experimental Sectionmentioning

confidence: 99%

Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases

Gill

Kirchhoff

et al. 2012

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…These steps can progress towards different clinical scenarios: spontaneous cure, disease, latent infection and re-activation, or re-infection (see Fig. 1; reviewed by Godreuil et al, 2007b). Immunosuppressed individuals are more at risk of developing active TB once infected, particularly patients with AIDS.…”

Section: Introductionmentioning

confidence: 99%

“…During the last 20 years, hundreds of candidate vaccines have been under study; however, none has passed the clinical trial phase (Ginsberg, 2002;Hampton, 2005;Kaufmann et al, 2006;Kaufmann, 2011Kaufmann, , 2012Kaufmann, , 2013. (2006) and Godreuil et al (2007b). MTB enters the host by inhalation of aerosols.…”

Section: Introductionmentioning

confidence: 99%

Mycobacterium tuberculosis: ecology and evolution of a human bacterium

Bañuls

Sanou

Anh

et al. 2015

Journal of Medical Microbiology

Self Cite

130

107

View full text Add to dashboard Cite

“…It can spread from person to person by the tuberculosis germs being propelled into the air through a cough, spit, or sneeze. 30 Just a few of these germs could infect a person with tuberculosis. Tuberculosis is one of the top 10 causes of death in the world.…”

Section: Bacteria-caused Infectious Diseasesmentioning

confidence: 99%

“…Many strategies have been invented for the diagnosis of tuberculosis disease. 30 In the early stages, active tuberculosis was diagnosed by culturing the tuberculosis bacteria; 32 however, it may take several weeks to get a result. Recently, people have also developed blood-based diagnostic methods to detect tuberculosis disease using immunology techniques that have higher sensitivity and specificity, 36 but the requirement of skilled technicians and expensive equipment makes it unsuitable in developing countries.…”

Section: Bacteria-caused Infectious Diseasesmentioning

confidence: 99%

Application of nanodiagnostics in point-of-care tests for infectious diseases

Wang¹,

Yu²,

Kong³

et al. 2017

IJN

103

View full text Add to dashboard Cite

Although tremendous efforts have been put into the treatment of infectious diseases to prevent epidemics and mortality, it is still one of the major health care issues that have a profound impact on humankind. Therefore, the development of specific, sensitive, accurate, rapid, low-cost, and easy-to-use diagnostic tools is still in urgent demand. Nanodiagnostics, defined as the application of nanotechnology to medical diagnostics, can offer many unique opportunities for more successful and efficient diagnosis and treatment for infectious diseases. In this review, we provide an overview of the nanodiagnostics for infectious diseases from nanoparticle-based, nanodevice-based, and point-of-care test (POCT) platforms. Most importantly, emphasis focused on the recent trends in the nanotechnology-based POCT system. The current state-of-the-art and most promising point-of-care nanodiagnostic technologies, including miniaturized diagnostic magnetic resonance platform, magnetic barcode assay system, cell phone-based polarized light microscopy platform, cell phone-based dongle platform, and paper-based POCT platform, for infectious diseases were fully examined. The limitations, challenges, and future trends of the nanodiagnostics in POCTs for infectious diseases are also discussed.

show abstract

Pulmonary Tuberculosis and Mycobacterium Tuberculosis: Modern Molecular Epidemiology and Perspectives

Cited by 17 publications

References 194 publications

Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases

Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases

Mycobacterium tuberculosis: ecology and evolution of a human bacterium

Application of nanodiagnostics in point-of-care tests for infectious diseases

Contact Info

Product

Resources

About